» Articles » PMID: 18026115

T Cell-encoded CD80 and 4-1BBL Induce Auto- and Transcostimulation, Resulting in Potent Tumor Rejection

Overview
Journal Nat Med
Date 2007 Nov 21
PMID 18026115
Citations 153
Authors
Affiliations
Soon will be listed here.
Abstract

To reject tumors, T cells must overcome poor tumor immunogenicity and an adverse tumor microenvironment. Providing agonistic costimulatory signals to tumor-infiltrating T cells to augment T cell function remains a challenge for the implementation of safe and effective immunotherapy. We hypothesized that T cells overexpressing selected costimulatory ligands could serve as cellular vehicles mediating powerful, yet constrained, anatomically targeted costimulation. Here, we show that primary human T cells expressing CD80 and 4-1BB ligand (4-1BBL) vigorously respond to tumor cells lacking costimulatory ligands and provoke potent rejection of large, systemic tumors in immunodeficient mice. In addition to showing costimulation of bystander T cells (transcostimulation), we show the effect of CD80 and 4-1BBL binding to their respective receptors in the immunological synapse of isolated single cells (autocostimulation). This new strategy of endowing T cells with constitutively expressed costimulatory ligands could be extended to other ligand-receptor pairs and used to enhance any targeted adoptive transfer therapy.

Citing Articles

CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity.

Kong Y, Li J, Zhao X, Wu Y, Chen L Front Immunol. 2025; 15():1519671.

PMID: 39850899 PMC: 11754230. DOI: 10.3389/fimmu.2024.1519671.


Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors.

James S, Chen S, Ng B, Fischman J, Jahn L, Boardman A Nat Biomed Eng. 2024; 8(12):1592-1614.

PMID: 39715901 DOI: 10.1038/s41551-024-01287-3.


CAR-macrophage: Breaking new ground in cellular immunotherapy.

Huang T, Bei C, Hu Z, Li Y Front Cell Dev Biol. 2024; 12:1464218.

PMID: 39421021 PMC: 11484238. DOI: 10.3389/fcell.2024.1464218.


Recent advancements in improving the efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy for hepatocellular carcinoma.

Ren T, Huang Y Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(2):1433-1446.

PMID: 39316087 DOI: 10.1007/s00210-024-03443-7.


PET/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies.

Singh S, Bhandari S, Siwakoti S, Kumar M, Singh R, Bhusal S Mol Imaging. 2024; 23:15353508241257924.

PMID: 38952399 PMC: 11208886. DOI: 10.1177/15353508241257924.